65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details


臨床試験数 : 482 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 90 - 標的パスウェイ数 : 211

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03366142
(ClinicalTrials.gov)
July 2, 20187/12/2017Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory PathologyUse of Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory PathologyLAD1Drug: UstekinumabNational Institute of Allergy and Infectious Diseases (NIAID)NULLRecruiting12 Years65 YearsAll20Phase 1/Phase 2United States
2NCT02199496
(ClinicalTrials.gov)
October 19, 201523/7/2014Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable ImmunodeficiencyAn Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable ImmunodeficiencyGastrointestinal Inflammation Associated With CVID;CVID EnteropathyBiological: Stelara (ustekinumab)National Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 Years75 YearsAll5Phase 1/Phase 2United States